sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate
OSMOPREP (sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate) by Bausch Health is clinical pharmacology osmoprep tablets, a dosing regimen containing 48 grams of sodium phosphate (32 tablets), induces diarrhea, which effectively cleanses the entire colon. First approved in 2006.
Drug data last refreshed 15h ago · AI intelligence enriched 17h ago
OsmoPrep is an oral tablet formulation containing sodium phosphate salts (dibasic anhydrous and monobasic monohydrate) approved in 2006 for bowel cleansing prior to colonoscopy. It works through osmotic effect, drawing water into the colon to induce evacuation and cleanse the entire colon within 1–3 hours per dose. The product represents a well-established, non-absorbed small molecule laxative.
Product is approaching loss of exclusivity in mid-2028, signaling contraction phase and likely reduction in commercial team size and investment.
CLINICAL PHARMACOLOGY OsmoPrep Tablets, a dosing regimen containing 48 grams of sodium phosphate (32 tablets), induces diarrhea, which effectively cleanses the entire colon. Each administration has a purgative effect for approximately 1 to 3 hours. The primary mode of action is thought to be…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing
Worked on OSMOPREP at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in ~2 years — expect lifecycle management and generic defense hiring
OsmoPrep offers limited career growth opportunity given its maturity and approaching loss of exclusivity; roles are primarily defensive and cost-focused rather than growth-oriented. Professionals joining should expect a 1–2 year transition window into a generic/post-LOE environment or movement to other franchise products.